Fig. 3
The combination of SW IV-134 and Cisplatin therapy leads to improved objective response rate and survival in an immune-competent ovarian cancer mouse model. An immune-competent allograft mouse model of ovarian cancer was established after right flank injection a 200 μL single cell suspension of 1 × 107 ID8-Luey cells. The mice were treated with the above 4 treatment regimen with vehicle being the control group. A, The tumors were measured every other day using digital calipers. The change in tumor volumes between the groups was statistically significant with the tumor volumes of the combination group being significantly lower than vehicle (p < 0.0001), SWIV-134 (p = 0.01) and cisplatin (p = 0.001) at 36 days. B, Kaplan-Meier survival curve of mice in (A). Survival of the combination treatment group was significantly longer than any other treatment group with median survival being 36, 34, 46 and 76 days in the vehicle, SW IV-134 alone, cisplatin alone and combination treatment groups, respectively (p < 0.001)